Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BioCrossroads

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 17
Rounds per year 1.00
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.15
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Life Science
Summary

The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Indianapolis.

The fund is generally included in less than 2 deals every year. The typical startup value when the investment from BioCrossroads is 1-5 millions dollars. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 1 - 5 millions dollars. The important activity for fund was in 2013.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the BioCrossroads, startups are often financed by National Institutes of Health, Elevate Ventures, Don Brown. The meaningful sponsors for the fund in investment in the same round are StepStone Angels, Spring Mill Venture Partners, Queen City Angels. In the next rounds fund is usually obtained by Triathlon Medical Venture Partners, Spring Mill Venture Partners, Prolog Ventures.

Among the most successful fund investment fields, there are Biotechnology, Diabetes. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight FlowCo, SpeechVive, Scioto Biosciences. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BioCrossroads:
Typical Co-investors
BioCrossroads is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BioCrossroads:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Baisheng Xinda China, Qingpu, Shanghai
Bull Partners Community of Madrid, Madrid, Spain
Capital Emprendedor Houston, Texas, United States
DreamFunded California, San Francisco, United States
Equitas Capital Advisors Louisiana, New Orleans, United States
Fides Capital partners Illinois, Lake Forest, United States
Hong Kong Yihe China, Hong Kong, Hong Kong Island
Hyundai Investment Partners Seoul, Seoul-t'ukpyolsi, South Korea
Intersect Partners LLC. Incline Village, Nevada, United States
Link Group Australia, New South Wales, Sydney
MobiKwik Gurgaon, Haryana, India
Momentum Investment Group Australia, Melbourne, Victoria
Mosaic Asset Management Irving, Texas, United States
PaRan GongCheng Beijing, Beijing, China
Puheng Touzi China, Jiangsu, Nanjing
Ronald Lauder Ventures -
Stocktwits New York, New York, United States
Sunfish Partners Mazowieckie, Poland, Warsaw
West Japan Railway Japan, Osaka, Osaka Prefecture
Zhonghui Hongcheng Touzi Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Lumavate

Customer Service
Marketing
Mobile Apps
Residential
SaaS
Software
$6M31 Jan 2022 Indiana, United States

Kovina Therapeutics

Biotechnology
Therapeutics
$2M20 Oct 2021 Indianapolis, Indiana, United States

Novosteo

Health Care
Pharmaceutical
$5M13 Jan 2021 Pennsylvania, United States

MBX Biosciences

Biotechnology
Health Care
Wellness
$34M27 Jul 2020 Indiana, United States

Sexton Biotechnologies

Biotechnology
$5M24 Sep 2019 Indianapolis, Indiana, United States

Lumavate

Customer Service
Marketing
Mobile Apps
Residential
SaaS
Software
$3M12 Jun 2019 Indiana, United States

Scioto Biosciences

Biotechnology
Diabetes
Health Care
Life Science
Therapeutics
$1M21 May 2018 Indianapolis, Indiana, United States

SonarMed

Biotechnology
Health Care
$3M24 Oct 2017 Indianapolis, Indiana, United States

Allinaire Therapeutics

Biotechnology
Health Care
Therapeutics
$1M27 Jan 2017 Cleveland, Ohio, United States
News
Novosteo Closes $5.5M in Series A Financing

– Novosteo Closes $5.5m in Series A Financing.
– The company raised $5.5m in Series A financing.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.

Research Bridge Partners' Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing

– Research Bridge Partners announced that one of its portfolio companies, Novosteo, Inc., closed $5.5m in Series A financing to further development of the first-ever targeted bone anabolic agent NOV004.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Novosteo, Inc.’s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BioCrossroads?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: